Browsing Genetics by Author "HUMPHRIES, PETER"
Now showing items 21-26 of 26
- Sort by:
- title
- issue date
- submit date
- Order:
- ascending
- descending
- Results:
- 5
- 10
- 20
- 40
- 60
- 80
- 100
-
Synaptic plasticity in GNGA3-/- mice: Cone bipolar cells react up0onthe missing cone input and form ectopic synapses with rods
HUMPHRIES, PETER (The Society for Neuroscience, 2006)In the mammalian retina, rods and cones connect to distinct sets of bipolar cells. Rods are presynaptic to a single type of rod bipolar cell, whereas cones connect to different types of cone bipolar cells. Synaptic rewiring ... -
Target 5000: Target capture sequencing for inherited retinal degenerations
FARRAR, JANE; HUMPHRIES, PETER (2017) -
Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10).
FARRAR, JANE; HUMPHRIES, MARIAN; HUMPHRIES, PETER; CAMPBELL, MATTHEW (2008)Mutations within the inosine 5'-monophosphate dehydrogenase 1 (IMPDH1) gene cause the RP10 form of autosomal dominant retinitis pigmentosa (adRP), an early-onset retinopathy resulting in extensive visual handicap owing to ... -
Toward an elucidation of the molecular genetics of inherited retinal degenerations
FARRAR, JANE; HUMPHRIES, PETER; HUMPHRIES, MARIAN (2017) -
Transplantation of syngeneic schwann cells to the retina of the rhodopsin knockout (Rho-/-) mouse
HUMPHRIES, PETER (The Association for Research in Vision and Ophthalmology, Inc., 2003)PURPOSE: To determine whether subretinal Schwann cell transplantation can prolong the survival of photoreceptors in the rhodopsin knockout (rho(-/-)) mouse. METHODS: Schwann cells were prepared from postnatal day (PN) 5 ... -
Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta
FARRAR, JANE; HUMPHRIES, PETER (Oxford University Press, 2002)Over 100 dominant-negative mutations within the COL1A1 gene have been identified in osteogenesis imperfecta (OI). In terms of human therapeutics, targeting each of these mutations independently is unlikely to be feasible. ...